Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: The role of iron overload

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 5, 2009, Pages 403-410

  Lecube, Albert ^a   Hernández, Cristina ^a   Simó, Rafael ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Glucose abnormalities; Hepatitis C virus; Iron overload; Liver steatosis

Indexed keywords

FERROPORTIN 1; GLUCOSE TRANSPORTER 4; HEMOJUVELIN; HEPCIDIN; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; FERRITIN; IRON;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETIC RETINOPATHY; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; HYPERFERRITINEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; IRON METABOLISM; IRON OVERLOAD; LIPID STORAGE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER NECROSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; BLOOD; FATTY LIVER; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; PATHOLOGY;

BLOOD GLUCOSE; FATTY LIVER; FERRITINS; HEPATITIS C, CHRONIC; HUMANS; IRON; IRON OVERLOAD; LIVER;

EID: 70350633968     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.972     Document Type: Review

References (104)

1. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75(4): 355-359. (Pubitemid 30187108)
2. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50(8): 1844-1850. (Pubitemid 33641605)
3. Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate análisis considering the liver injury. Diabetes Care 2004; 27(5): 1171-1175. (Pubitemid 38579785)
4. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30(5): 1212-1218. (Pubitemid 46684650)
5. Salonen JT, Tuomainen TP, Nyyssönen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 1998; 317(7160): 727. (Pubitemid 28414303)
6. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 291(6): 711-717. (Pubitemid 38543791)
7. Haque S, Chandra B, Gerber MA, Lok AS. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Human Pathol 1996; 27(12): 1277-1281. (Pubitemid 26415319)
8. Riggio O,Montagnese F, Fiore P, et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol 1997; 92(8): 1298-1301. (Pubitemid 27328587)
9. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114(2): 311-318. (Pubitemid 28093538)
10. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96(8): 2448-2455. (Pubitemid 32769210)
11. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39(1): 179-187. (Pubitemid 38461480)
12. Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol 2004; 99(2): 286-291. (Pubitemid 38279871)
13. Fernández-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999; 42(11): 1367-1374. (Pubitemid 29500975)
14. Hernández C, Lecube A, Carrera A, Simó R. Soluble transferrin receptors and ferritin in Type 2 diabetic patients. Diabet Med 2005; 22(1): 97-101. (Pubitemid 40188294)
15. Emerit J, Beaumont C, Trivin F. Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother 2001; 55(6): 333-339. (Pubitemid 32595478)
16. Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51(8): 2348-2354.
17. Haap M, Fritsche A, Mensing HJ, Haring HU, Stumvoll M. Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Ann Intern Med 2003; 139(10): 869-871.
18. Cook JD. Adaptation in iron metabolism. Am J Clin Nutr 1990; 51(2): 301-308.
19. Jiang R, Ma J, Ascherio A, Stampfer MJ, Willet WC, Hu FB. Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: a prospective cohort study. Am J Clin Nutr 2004; 79(1): 70-75.
20. Lee DH, Folsom AR, Jacobs DR Jr. Dietary iron intake and type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia 2004; 47(2): 185-194. (Pubitemid 38315354)
21. Rajpathak S, Ma J, Manson J, WillettWC, Hu FB. Iron intake and the risk of type 2 diabetes in women. A prospective cohort study. Diabetes Care 2006; 29(6): 1370-1376. (Pubitemid 44125937)
22. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Lopez-Bermejo A, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care 2002; 25(12): 2249-2255. (Pubitemid 41071036)
23. Zheng H, Patel M, Cable R, Young L, Katz SD. Insulin sensitivity, vascular function, and iron stores in voluntary blood donors. Diabetes Care 2007; 30(10): 2685-2689.
24. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci 2003; 325(6): 332-339.
25. Zacharski L, Ornstein D, Woloshin S, Schwartz L. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000; 140(1): 98-104. (Pubitemid 30471247)
26. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 291(6): 711-717. (Pubitemid 38543791)
27. Ford ES, Cogswell ME. Diabetes and serum ferritin concentrations among U.S. adults. Diabetes Care 1999; 22(12): 1978-1983. (Pubitemid 30433975)
28. Lecube A, Hernández C, Genescà J, et al. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Diabetes Care 2004; 27(11): 2669-2675. (Pubitemid 39441468)
29. Dinneen SF, Silverberg JD, Batts KP, O'Brien PC, Ballard DJ, Rizza RA. Liver iron stores in patients with non-insulin-dependent diabetes mellitus. Mayo Clin Proc 1994; 69(1): 13-15. (Pubitemid 24016909)
30. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117(5): 1155-1163. (Pubitemid 29512675)
31. Lecube A, Hernández C, Genescà J, Simo R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care 2006; 29(5): 1140-1149. (Pubitemid 44115262)
32. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340(6): 448-454. (Pubitemid 29084777)
33. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8(3): 521-533. (Pubitemid 39141140)
34. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40(6): 1387-1395. (Pubitemid 39657013)
35. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005; 42(1): 44-52. (Pubitemid 40911310)
36. Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999; 19(4): 299-304. (Pubitemid 29359094)
37. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96(10): 2957-2961. (Pubitemid 32959539)
38. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107(5): 450-455. (Pubitemid 29528333)
39. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(4): 917-923. (Pubitemid 36397405)
40. Riva A, Trombini P, Mariani R, et al. Revaluation of clinical and histological criteria for diagnosis of dysmetaboic iron overload. World J Gastroenterol 2008; 14(30): 4745-4752.
41. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 1989; 24(Pt 1): 275-302.
42. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85(10): 1349-1355. (Pubitemid 20360647)
43. Day CP. Nonalcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006; 6(1): 19-25. (Pubitemid 43302594)
44. Targher G, Arcaro G. Nonalcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191(2): 235-240. (Pubitemid 46400718)
45. Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51(3): 444-450.
46. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42(2): 473-480. (Pubitemid 41061101)
47. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of non-alcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004; 27(10): 2498-2500. (Pubitemid 39281410)
48. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander- Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94(9): 2467-2474.
49. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin secretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35(2): 373-379. (Pubitemid 34106377)
50. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51(4): 1000-1004. (Pubitemid 34438342)
51. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122(4): 931-939.
52. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. Am J Clin Pathol 2001; 116(2): 263-270. (Pubitemid 33044332)
53. Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986; 261(19): 8708-8711.
54. Tanner LI, Lienhard GE. Insulin elicits a redistribution of transferrin receptors in 3T3-L1 adipocytes through an increase in the rate constant for receptor externalization. J Biol Chem 1987; 262(19): 8975-8980.
55. Aigner E, Theurl I, Theurl M, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008; 87(5): 1374-1383. (Pubitemid 351679780)
56. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: relationship to HFEmutations. Am J Gastroenterol 2000; 95(7): 1788-1793.
57. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17(3): 189-212. (Pubitemid 32624602)
58. Green A, Basile R, Rumberger JM. Transferrin and iron induce insulin resistance of glucose transport in adipocytes. Metabolism 2006; 55(8): 1042-1045. (Pubitemid 44026544)
59. Trombini P, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. J Hepatol 2007; 46(4): 549-552. (Pubitemid 46415626)
60. Day CP, James OF. Steatohepatitis: a tale of 'two-hits'? Gastroenterology 1998; 114(4): 842-845.
61. George DK, Goldwurm S, Macdonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114(2): 311-318. (Pubitemid 28093538)
62. Brown KE, Dennery PA, Ridnour LA, et al. Effect of iron overload and dietary fat on indices of oxidative stress and hepatic fibrogenesis in rats. Liver Int 2003; 23(4): 232-234.
63. Cornejo P, Varela P, Videla LA, Fernandez V. Chronic iron overload enhances inducible nitric oxide synthase expression in rat liver. Nitric Oxide 2005; 13(1): 54-61. (Pubitemid 40853969)
64. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol 1998; 28(Suppl 1): 8-13. (Pubitemid 28168254)
65. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116(6): 1413-1419. (Pubitemid 29258890)
66. Kirsch R, Sijtsema HP, Tlali M, Marais AD, Hall Pde L. Effect of iron overload in a rat nutritional model of non-alcoholic fatty liver disease. Liver Int 2006; 26(10): 1258-11162 (Pubitemid 44741214)
67. Yamamoto M, Iwasa M, Iwata K, et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22(4): 498-503. (Pubitemid 46434977)
68. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36(1): 142-149. (Pubitemid 34700771)
69. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21(1): 62-68. (Pubitemid 28030387)
70. Lecube A, Hernández C, Pelegrí D, Simó R. Factors accounting for high ferritin levels in obesity. Int J Obes (Lond) 2008; 32(11): 1665-1669.
71. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44(1): 45-51. (Pubitemid 28042465)
72. Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003; 124(3): 866-867. (Pubitemid 36268503)
73. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102(6): 1251-1258. (Pubitemid 46802029)
74. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect 2000; 4(12): 1219-1225.
75. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341(8): 556-562.
76. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123(8): 615-620.
77. Nocente R, Ceccanti M, Bertazzoni G, Cammarota G, Silveri NG, Gasbarrini G. HCV infection and extrahepatic manifestations. Hepatogastroenterology 2003; 50(52): 1149-1154.
78. Grimbert S, Valensi P, Levy-Marchal C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 1996; 20(6-7): 544-548. (Pubitemid 26247719)
79. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30(4): 1059-1063. (Pubitemid 29458297)
80. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133(8): 592-599. (Pubitemid 30778446)
81. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38(1): 50-56. (Pubitemid 36775795)
82. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126(3): 840-848. (Pubitemid 38298332)
83. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22(4): 449-456.
84. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78(Pt 7): 1527-1531. (Pubitemid 27343089)
85. Itoh Y, Okanoue T, Ohnishi N, et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1999; 94(5): 1332-1340. (Pubitemid 29214650)
86. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. World J Gastroenterol 2007; 13(35): 4699-4706. (Pubitemid 47455560)
87. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26: 323-342.
88. Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expresión in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 2007; 13(1-2): 97-104. (Pubitemid 46786838)
89. Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134(1): 226-238. (Pubitemid 350309316)
90. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48(5): 1420-1429.
91. Fujita N, Sugimoto R, Motonishi S, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 2008; 49(5): 702-710.
92. Saito H, Fujimoto Y, Ohtake T, et al. Up-regulation of transferring receptor 1 in chronic hepatitis C: implication in excess hepatic iron accumulation. Hepatol Res 2005; 31(4): 203-210. (Pubitemid 40724077)
93. Giannini E, Mastracci L, Botta F, et al. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. Eur J Gastroenterol Hepatol 2001; 13(11): 1355-1361. (Pubitemid 33111983)
94. Hernández C, Genescà J, Esteban JI, García L, Simó R. Relationship between iron stores and diabetes mellitus in patients infected by hepatitis C virus: a case-control study. Med Clin (Barc) 2000; 115(1): 21-22.
95. Garrido Serrano A, Guerrero Igea FJ, Lepe Jiménez JA, Palomo Gil S, Grilo Reina A. Hepatitis C virus infection, increased serum, ferritin and hyperinsulinemia. Rev Esp Enferm Dig 2001; 93(10): 639-648. (Pubitemid 33115075)
96. Iwasa M, Kaito M, Ikoma J, et al. Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. Hepatogastroenterology 2002; 49(44): 529-531. (Pubitemid 34606588)
97. Iwasa M, Iwata K, Kaito M, et al. Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C virus. Nutrition 2004; 20(4): 368-371. (Pubitemid 38388511)
98. Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22(3): 269-275. (Pubitemid 34846366)
99. Quinn PG, Jamal MM, Carey JD, et al. A case-control study of the factors associated with spontaneous resolution of hepatitis C viremia. Am J Gastroenterol 1999; 94(3): 668-673. (Pubitemid 29124864)
100. Paris R. Association of hepatitis C and diabetes mellitus. Ann Intern Med 2001; 135(2): 141-142.
101. Arber N, Konikoff FM, Moshkowitz M, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994; 39(12): 2656-2659.
102. Garrido Serrano A, Guerrero Igea FJ, Lepe Jiménez JA, Palomo Gil S, Grilo Reina A. Hyperinsulinemia in cirrhotic patients infected with hepatitis C virus infection. Gastroenterol Hepatol 2001; 24(3): 127-131. (Pubitemid 33115075)
103. Fernández-Re0al JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24(3): 278-301.
104. Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35(2): 279-283. (Pubitemid 32803485)